**Author details**

## Omid Gholami

Address all correspondence to: omidghphd@gmail.com

Department of Physiology and Pharmacology, Faculty of Medicine, Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

[10] Faguet GB. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis,

Cytotoxicity and Apoptosis Induction by Coumarins in CLL

http://dx.doi.org/10.5772/intechopen.72446

107

[11] Contri A, Brunati AM, Trentin L, Cabrelle A, Miorin M, Cesaro L, et al. Chronic lymphocytic leukemia B-cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis. The Journal of Clinical Investigation. 2005 Feb;**115**(2):369-378.

[12] Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood. 2008 Jan 15;**111**(2):846-855. PubMed

[13] Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. Journal of

[14] Gobessi S, Laurenti L, Longo PG, Sica S, Leone G, Efremov DG. ZAP-70 enhances B-cellreceptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood. 2007 Mar 01;**109**(5):2032-2039. PubMed

[15] Pleyer L, Egle A, Hartmann TN, Greil R. Molecular and cellular mechanisms of CLL: Novel therapeutic approaches. Nature Reviews. Clinical Oncology. 2009 Jul;**6**(7):405-

[16] Carlo-Stella C, Lavazza C, Locatelli A, Vigano L, Gianni AM, Gianni L. Targeting TRAIL agonistic receptors for cancer therapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2007 Apr 15;**13**(8):2313-2317. PubMed

[17] Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Current Opinion in Immunology. 2007 Oct;**19**(5):488-496. PubMed PMID: 17629468.

[18] Mackus WJ, Kater AP, Grummels A, Evers LM, Hooijbrink B, Kramer MH, et al. Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation.

[19] Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, et al. p53 and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa.

[20] Yin XM, Wang K, Gross A, Zhao Y, Zinkel S, Klocke B, et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature. 1999 Aug 26;**400**(6747):886-891.

[21] Dicker F, Kater AP, Prada CE, Fukuda T, Castro JE, Sun G, et al. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood. 2006 Nov 15;**108**(10):3450-3457. PubMed PMID: 16741250. Pubmed

Leukemia. 2005 Mar;**19**(3):427-434. PubMed PMID: 15674362

Science. 2003 Nov 07;**302**(5647):1036-1038. PubMed PMID: 14500851

Immunology. 1999 Jun 15;**162**(12):7088-7094. PubMed PMID: 10358152

and Management. New Jersey: Humana Press; 2004

PMID: 17928528

PMID: 17038529

PMID: 17438088

418. PubMed PMID: 19488076

Pubmed Central PMCID: 2754308

PubMed PMID: 10476969

Central PMCID: 1895435

PubMed PMID: 15650771. Pubmed Central PMCID: 544036
